See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

HotSpot Therapeutics Presents Preclinical Data From Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal ...

Summary by World News
BOSTON, July 4, 2025 /PRNewswire/

13 Articles

Rutland HeraldRutland Herald
+11 Reposted by 11 other sources
Center

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025

BOSTON, July 4, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," today announced the presentation…

Read Full Article
World NewsWorld News
Center

HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal ...

BOSTON, July 4, 2025 /PRNewswire/

·United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 56% of the sources are Center
56% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

World News broke the news in United States on Friday, July 4, 2025.
Sources are mostly out of (0)

Similar News Topics

Boston, Massachusetts icon

Boston, Massachusetts

News
For You
SearchBlindspotLocal